Selling pressure pushes UnitedHealth stock lower in today's trading

Traders Union
All News
Financial News
Unitedhealth slides 2.86% today

Highlights

UnitedHealth exceeded Q1 2026 earnings expectations and raised its full-year guidance, driven by disciplined Medicare Advantage cost management.
Growth in the Optum division, launch of a new transparent pharmacy model, and capital returns via dividends and buybacks supported performance despite ongoing share price pressure.
Technical indicators show mixed momentum with near-term selling, but the stock is projected to trade between $371.19 and $387.12 over the next week.

Earnings beat and Optum gains as shares face selling pressure

UnitedHealth reported stronger-than-expected first-quarter results for 2026 and raised its full-year adjusted earnings outlook. The company’s performance was driven by a focus on managing Medicare Advantage costs and leveraging its Optum division in care delivery, pharmacy benefit management, and analytics services. Additional developments included the launch of a new transparent pharmacy care model by Optum Rx and a continued emphasis on shareholder returns through dividends and buybacks, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, views the recent decline in UnitedHealth as a reflection of mounting short-term pressure. He points to mixed technical momentum and a concerning gap-down open as warning signals. The analyst notes that although fundamental drivers like strong earnings and share buybacks are present, the stock's overbought technical readings increase downside risk. Persistent selling pressure and signs of investor caution could outweigh bullish longer-term trends. "Despite appealing fundamentals, my stance is defensive until momentum fully confirms any recovery," Kharitonov warns.

Viktoras Karapetjanc, expert at Traders Union, highlights UnitedHealth’s upbeat earnings and raised outlook as strong signals of operational strength. He emphasizes that the Optum division’s innovation and sustained shareholder rewards support a bullish structure. Karapetjanc sees room for further growth, with most weekly momentum indicators validating an upside scenario. "I expect bullish forces and recent fundamental wins to keep UnitedHealth on track for higher prices," Karapetjanc states confidently.

Jainam Mehta, market strategist, notes the mixed technical signals and recent volatility after UnitedHealth’s gap-down move. He sees the stock as rangebound for now, with both upside and downside scenarios live. Tactically, Mehta suggests watching $383 resistance for upside momentum, and $371 for signs of further weakness. "A break on either side of this corridor may offer tactical setups for agile traders," Mehta advises.

Mixed technical momentum as intraday selling contrasts with bullish trend

Momentum signals display a mixed picture. While MACD and Average Directional Index (ADX) on the daily chart show bullish momentum, oscillators such as the Relative Strength Index (RSI) and Commodity Channel Index (CCI) indicate that UNH is approaching overbought levels, with the Stochastic RSI presenting strong oversold conditions. Bull/Bear Power (BBP) is still positive, supporting buyer dominance, but also points to an overbought setting. The Awesome Oscillator is neutral, adding no strong signal. Intraday, UnitedHealth slipped $11.13 or 2.86%, opening with a downside gap of about $6.66 and currently trades near the daily low, as intraday volatility stands at 1.69%. Intraday pressure continues after the gap-down open, reflecting short-term selling not fully confirmed by broader momentum indicators.

Earlier, analysts noted that UnitedHealth maintained a bullish medium-term trend but cautioned that overbought conditions could increase the risk of short-term volatility. Current market action adds a new dimension, as the recent gap-down and heightened intraday pressure highlight the importance of monitoring support at $371, where a downside break could accelerate selling, while a reclaim of resistance at $383 may reignite bullish momentum.

Source of Data: UNH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.